Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006264
Abstract: Somatic mutations of calreticulin (CALR)have been identified as one of the main disease drivers of myeloproliferative neoplasms (MPNs), suggesting that developing drugs targeting mutant CALR is of great significance. Site-directed mutagenesis in the N-glycan binding… read more here.
Keywords: calr; mutant calr; thrombopoietin receptor; interaction ... See more keywords
Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016846
Abstract: Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino-acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact… read more here.
Keywords: cell; calr; mutant calr; calr proteins ... See more keywords
Targeting human CALR‐mutated MPN progenitors with a neoepitope‐directed monoclonal antibody
Sign Up to like & getrecommendations! Published in 2022 at "EMBO Reports"
DOI: 10.15252/embr.202152904
Abstract: Calreticulin (CALR) is recurrently mutated in myelofibrosis via a frameshift that removes an endoplasmic reticulum retention signal, creating a neoepitope potentially targetable by immunotherapeutic approaches. We developed a specific rat monoclonal IgG2α antibody, 4D7, directed… read more here.
Keywords: targeting human; calr; human calr; mutant calr ... See more keywords